CompletedNCT04624243
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
Medication studyAges 18–55Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Bentonville, United States · Little Rock, United States and 90 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo described in the protocol; its role is not resolved here
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: December 15, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 499
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria, Croatia, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT04624243
- Official title
Show the full official title
A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia
Recruitment & locations
CompletedBentonville, United States · Little Rock, United States · Rogers, United States
89 more locations
- Bellflower, United States
- Culver City, United States
- Garden Grove, United States
- Glendale, United States
- Riverside, United States
- San Diego, United States
- Sherman Oaks, United States
- Hollywood, United States
- Miami, United States
- Miami Lakes, United States
- Oakland Park, United States
- Stuart, United States
- Atlanta, United States
- Decatur, United States
- Chicago, United States
- Shreveport, United States
- Gaithersburg, United States
- Boston, United States
- St Louis, United States
- Las Vegas, United States
- Marlton, United States
- Staten Island, United States
- Charlotte, United States
- Dayton, United States
- North Canton, United States
- Austin, United States
- Richardson, United States
- Novi Iskar, Bulgaria
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Veliko Tarnovo, Bulgaria
- Zagreb, Croatia
- Rijeka, Croatia
- Toyoake, Japan
- Ichikawa, Japan
- Kitakyushu, Japan
- Omuta, Japan
- Tomioka, Japan
- Atsugi, Japan
- Hadano, Japan
- Yokohama, Japan
- Komoro, Japan
- Kunigamigun, Japan
- Naha, Japan
- Kanzaki-gun, Japan
- Karatsu, Japan
- Hachiōji, Japan
- Kita-ku, Japan
- Kodaira, Japan
- Chiba, Japan
- Fukuoka, Japan
- Kumamoto, Japan
- Tokyo, Japan
- Daugavpils, Latvia
- Liepāja, Latvia
- Poznan, Poland
- Pruszków, Poland
- Warsaw, Poland
- Gdansk, Poland
- Lodz, Poland
- Bucharest, Romania
- Iași, Romania
- Arkhangelsk, Russia
- Leningrad Region, Russia
- Lipetsk, Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Stavropol, Russia
- Tomsk, Russia
- Yaroslavl, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Kovin, Serbia
- Busan, South Korea
- Daegu, South Korea
- Seoul, South Korea
- Taichung, Taiwan
- Taipei, Taiwan
- Taoyuan, Taiwan
- Smila, Ukraine
- Dnipro, Ukraine
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Vinnytsia, Ukraine
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Merck Sharp & Dohme LLC.
Did this study involve medication?
Yes. The study involved medication, including Elpipodect, Risperidone, Placebo to MK-8189 and Placebo to risperidone.
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
United States
CompletedNCT06880328
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in people with Schizophrenia
United States
CompletedEUCTR 2016-000061-23
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
Poland, Slovakia